Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06717425 | A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity | PHASE2 | COMPLETED | 263 | — | — | Dec 9, 2024 | Jan 12, 2026 | Feb 6, 2026 | 38 | United States, Canada +1 |
| Arm | Type | Description |
|---|---|---|
| PF-07976016 Dose 1 | EXPERIMENTAL | - |
| PF-07976016 Dose 2 | EXPERIMENTAL | - |
| PF-07976016 Dose 3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-07976016 | DRUG | Taken once daily |
| Placebo | DRUG | Taken once daily |
Key Inclusion Criteria: * Male or non-pregnant, non-breastfeeding female, 18 to 74 years of age at Visit 1 * Body Mass Index ≥30.0 kg/m2 at Visit 1, with stable body weight, defined as \<5 kg change in the 12 weeks before Visit 1 * Eligible and willing to receive required background medicine * Will...